Study of Roxadustat in the Treatment of Acute Myocardial Infarction

• Status: Recruiting
• Trial end date: 2023-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Depite successful primary percutaneous coronary intervention (PCI) and standardized medical treatment, prognosis of acute ST-elevation myocardial infarction patents are still a poor, with high morality and various complications such as heart failure. Roxadustat is a new drug targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition and has shown promising effect in reducing infarct size in pre-clinical studies.

This study aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elevation myocardial infarction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital

Criteria

Inclusion Criteria:

• Acute STEMI (ST segment elevation myocardial infarction) diagnosed by ST elevation

• Coronary angiography within 12 hours of symptom onset, with TIMI flow grade 0 - 1 of culprit vessel

• Primary PCI with TIMI flow grade 2 - 3 after successful intervention

• Capable and willing to provide informed consent and capable of completing study visits

Exclusion Criteria:

• Previous acute myocardial infarction history

• Cardiogenic Shock at admission

• Previously treated by roxadustat

• Contraindications of roxadustat treatment

• Contraindication of Cardiac MRI (e.g. eGFR < 30 ml/min, pacemaker, metal prosthesis, etc.)